Boomerang Therapeutics
Personalized Cancer Gene Therapy
Company Overview
Snapshot
Founded in March 2015 by Ori Zelichov and Shai Duchin, Boomerang Therapeutics operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing a genetic device for personalized cancer therapy. In September 2015, the company's student team won a top prize at Boston's Genetically Engineered Machine Competition, highlighting early recognition for its innovative approach.
Business overview
Boomerang Therapeutics is a Health Tech & Life Sciences company specializing in personalized cancer gene therapy. The company develops a genetic device that utilizes advanced gene editing tools, specifically CRISPR technology, to eliminate cancer cells by activating suicide genes. This system is designed to be tailored to the genetic profile of each patient's tumor, paving the way for highly personalized treatment approaches within the pharmaceuticals and life sciences sectors.
Strategic signal
In February 2016, Boomerang Therapeutics was featured by IDT DNA for its innovative approach to targeting cancer treatments to cancer cells. This recognition from a prominent synthetic biology solutions provider signals external validation of the company's scientific methodology and potential impact in the field of personalized medicine, suggesting a promising trajectory for its gene editing technology.
Log in to access full profile ›Company Intelligence Q&A
- When was Boomerang Therapeutics founded?
- Boomerang Therapeutics was founded in March 2015.
- Who are the founders of Boomerang Therapeutics?
- The company was founded by Ori Zelichov and Shai Duchin.
- What is Boomerang Therapeutics' core technology?
- Boomerang Therapeutics develops a genetic device for cancer therapy using advanced gene editing tools, specifically CRISPR, to activate suicide genes in cancer cells.
- What recognition did Boomerang Therapeutics receive in September 2015?
- In September 2015, Boomerang Therapeutics' student team won a top prize in Boston's Genetically Engineered Machine Competition.
- What was the focus of the February 2016 article featuring Boomerang Therapeutics?
- In February 2016, IDT DNA featured Boomerang Therapeutics for its work on targeting cancer treatments to cancer cells, highlighting its innovative approach in synthetic biology.